PUBLIC COMPANY
saveAstellas Pharma Inc
updated 2mo ago
Astellas Pharma Inc. is a Japanese multinational pharmaceutical company, formed on 1 April 2005 from the merger of Yamanouchi Pharmaceutical Co., Ltd. and Fujisawa Pharmaceutical Co., Ltd. .
community read0 votes
🐶 often sniffed alongside
top 5pipeline
8
marketed
1
phase 3
0
catalysts ytd
1
approvals ytd
1
recalls ytd
0
Pipeline(8)
pipeline depth8 products
4Phase 21Marketed3Unknown
Marketed
enfortumab vedotin
Muscle Invasive Bladder Cancer (MIBC)
Nectin-4Tubulin
Phase 2ASP-2957
X-Linked Myotubular Myopathy (XLMTM or MTM)
Phase 2ASP-7316
Juvenile Macular Degeneration (Stargardt Disease)
Phase 2zocaglusagene nuzaparvovec
Pompe Disease
Phase 2zolbetuximab
Metastatic Adenocarcinoma of The Pancreas
Claudin-18
drugIZERVAY
drugPADCEV
drugXTANDI
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase4A Study About the Safety of ASP3021 Eye Injections and if They Help People in Japan With Vision Loss From Age-related Macular Degeneration
- phase1A Study of ASP3082 in Adults With Advanced Solid Tumors
- phase2A Study of ASP2246 for People Who Have Movement Problems Caused by Brain Injury After a Stroke
- phase1A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
- phase3A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) Mutation
- phase3A Study to Assess Long-term Safety of Fezolinetant Given to Japanese Women Going Through Menopause
- —Japan Post-Marketing Surveillance for Peficitinib to Assess Safety and Effectiveness in the Patients With Rheumatoid Arthritis
- phase1A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumors
🐶 Hiring Signal
News
- 2 Massachusetts biotechs call it quitsAdecto Pharmaceuticals has ceased operations, while Aviceda Therapeutics is in the process of winding down.biospace · 2h ago
- Foghorn cuts 40% of workforceFollow along as BioSpace tracks job cuts and restructuring initiatives.biospace · 3d ago
- Sling banks $123M for an experimental thyroid eye disease pillA confirmatory late-stage study is now also underway for what the startup is positioning as, potentially, the first oral alternative to approved injectables like Amgen's Tepezza and Viridian's Lumvoa.biopharma_dive · 19d ago
- Drugmakers cherry pick launch regions as MFN creates 'policy environment like an earthquake'With multiple drug pricing initiatives like Most Favored Nation now in force, drugmakers have to reinvent their commercial strategies to stay ahead of the fast-moving policy environment, according…biospace · 25d ago
- Novartis’ and BMS’ paused CAR T trials, RevMed’s pancreatic cancer approval, more MFN dealsNovartis hits pause on several CAR T trials after three patient deaths, followed by Bristol Myers Squibb after separate safety signals; Revolution Medicines scores early FDA approval for groundbrea…biospace · 1mo ago
- Mid-cap biotechs join Trump’s latest round of drug pricing dealsFocused on Medicaid, the new pacts now involve more than just large pharmaceutical companies, but still aren’t expected to meaningfully impact drugmaker profits.biopharma_dive · 1mo ago
- 9 midsize drugmakers climb aboard Trump’s MFN trainAstellas Pharma, BridgeBio, BeOne Medicines and six other large biotechs join the 17 Big Pharmas that previously signed on to President Donald Trump’s Most Favored Nation (MFN) drug pricing program…biospace · 1mo ago
- Will a ‘reset’ reignite investment in women’s health startups?After peaking in 2024, venture investments in startups involved in the space declined last year. But a broader adoption of AI and a widening definition of what constitutes women’s health could spur…biopharma_dive · 1mo ago
- PTC takes a chance on Sangamo’s Fabry disease gene therapyWall Street analysts view the deal as a risky, high-reward bet on a treatment that’s nearing a possible regulatory approval and could be superior to existing medications.biopharma_dive · 1mo ago
- Silence cashes in on ‘differentiated’ data; UK reaffirms support for childhood vaccinesSome analysts believe Silence’s polycythemia vera drug could be superior to a closely watched Takeda medicine. Elsewhere, the FDA spurned a radiopharmaceutical and AbCellera shares climbed to level…biopharma_dive · 1mo ago
Data sources
Found something off?
comments(0)
5-min edit window · permanent after that